Immediate results of medicine Slavinorm treatment in patients with atherosclerotic arteries diseases of the lower extremities

Close metadata

OBJECTIVE

To evaluate the effect of the drug Slavinorm on the immediate results of treatment and to develop a treatment algorithm for patients with diseases of the arteries of the lower extremities of atherosclerotic etiology.

MATERIAL AND METHODS

The study included 78 patients with obliterating atherosclerosis of the arteries of the lower extremities, stage IIb of the disease according to A.V. Pokrovsky-Fontein, which were divided into two comparable groups. Patients were monitored from the moment of diagnosis of obliterating atherosclerosis and the start of therapy, and for 3 months. All patients were divided into two groups. In group 1 (38 patients), the treatment method was basic therapy (acetylsalicylic acid, atorvastatin, antihypertensive drugs)+Slavinorm intramuscularly, at a dose of 5 mg, 2 times per week, with a treatment period of 5 weeks (10 doses). In group 2 (40 patients), the method of correcting blood flow was basic therapy (acetylsalicylic acid, atorvastatin, antihypertensive drugs)+pentoksyphylline, according to the National recommendations for the management of patients with peripheral arterial diseases.

RESULTS

In patients of the first group, 3 months after the first injection of the drug, there was an increase in pain-free walking distance (PFWD) by 35—40 m in 22 patients (57.89%), in 12 patients (31.58%) there was an increase in PFWD by 15―10 m and in 4 patients (10.53%) without dynamics. According to ultrasound data, in both groups there was a significant increase in ABI from 0.7 to 0.8 (p<0.001) 2 month from the start of treatment. After 3 months, in the group using the drug Slavinorm, the ABI indicator stays at the same level as after 2 months (p>0.05). In the control group, after 3 months there was a decrease in Ankle-brachial index (ABI) from 0.8 to 0.7 (p=0.006). At the same time, 25% of patients in the second group have a level of increase in laser Doppler flowmetry (LDF) above 60%, while in the first group this level of increase is minimal, and 75% of patients have an increase in LDF above 120%. The median level in the first group is also 2 times higher than the value of the second group.

CONCLUSION

The inclusion of Slavinorm in conservative therapy helps to improve microcirculation, increase the volume of the microvasculature by 128% and increase the distance of pain-free walking.

Keywords:

diseases of the arteries of the lower extremities

Slavinorm

endothelial dysfunction

peptides

Authors:

Katelnitsky I.I.

Rostov State Medical University of the Ministry of Health of the Russian Federation

ORCID: 0000-0002-3745-9064

Katelnitskaya E.S.

Rostov State Medical University of the Ministry of Health of the Russian Federation

ORCID: 0000-0002-1148-1044

Received:

10.10.2024

Accepted:

13.12.2024

List of references:

Kalinin RE, Suchkov IA, Chobanyan AA. Prospects for predicting the course of obliterating atherosclerosis of the arteries of the lower extremities. Science of the Young (Eruditio Juvenium). 2019;7(2):274-282. (In Russ.). https://doi.org/10.23888/HMJ201972274-282
Kalinin RE, Suchkov IA, Porsheneva EV, Krylov AA. Prospects for the use of cilostazol in the complex treatment of patients with obliterating atherosclerosis of the arteries of the lower extremities. Science of the Young (Eruditio Juvenium). 2021;9(4):619-630. (In Russ.). https://doi.org/10.23888/HMJ202194619-630
Kharazov AF, Kalyaev AO, Isaev AA. Prevalence of symptomatic lower limb ischemia in the Russian Federation. Pirogov Russian Journal of Surgery. 2016;7:58-61. (In Russ.). https://doi.org/10.17116/hirurgia2016758-61
Conte MS, Bradbury AS, Kolh Ph, et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery. 2019;69(6S):3S-125S.e40. https://doi.org/10.1016/j.jvs.2019.02.016
Kalinin RE, Suchkov IA, Klimentova EA, et al. Biomarkers of apoptosis and cell proliferation in the diagnosis of atherosclerosis progression in various vascular beds. Pavlov Russian Medical and Biological Bulletin. 2022;30(2):243-252. (In Russ.). https://doi.org/10.17816/PAVLOVJ88938
National guidelines for diagnosis and treatment of lower extremity arterial diseases. M. 2019;89. (In Russ.).
Hess CN, Huang Z, Patel MR, et al. Acute Limb Ischemia in Peripheral Artery Disease. Circulation. 2019;140(7):556-565. https://doi.org/10.1161/CIRCULATIONAHA.119.039773
Armstrong EJ, Wu J, Singh GD, et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg. 2014;60(6):1565-1571. https://doi.org/10.1016/j.jvs2014.08.064
Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329-1340. https://doi.org/10.1016/S0140-6736(13)61249-61250
Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2008;(4):CD000990. https://doi.org/10.1002/14651858.CD000990.pub2
Suchkov IA, Kalinin RE, Gadzhimuradov RU, et al. Clinical study of the efficacy and safety of Aducil in chronic lower limb ischemia. Angiology and vascular surgery. 2019;25(3):29-36. (In Russ.). https://doi.org/10.33529/ANGIO2019305
Mel’nikova YuS, Makarova TP. Endothelial dysfunction as the key link of chronic diseases pathogenesiS. Kazan Medical Journal, 2015;96:4. (In Russ.). https://doi.org/10.17750/KMJ2015-659
Shikh EV, Rebrova EV. Endothelial dysfunction and regulatory peptides. Russian Journal of Cardiology and Cardiovascular Surgery. 2023;16:2:205-210. (In Russ.). https://doi.org/10.17116/kardio202316021205
Kuznik BI, Mishchenko VP, Khavinson VKh, et al. Effect of the vascular wall polypeptide factor «vasonin» on the state of the hemostasis system in experimental peroxidation syndrome. Pharmacology and toxicology. 1986;6:39-43. (In Russ.).
Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Postgraduate Medical Journal. 2008;84(993):368-371. https://doi.org/10.1136/hrt.2005.066936
Patel KK, Jones PG, Ellerbeck EF, Buchanan DM, Chan PS, Pacheco CM, et al. Underutilization of evidence-based smoking cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care: insights from the international PORTRAIT registry. J Am Heart Assoc. 2018;7(20):010076. https://doi.org/10.1161/JAHA.118.010076
Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circulation Research. 2000;87(10):840-844. https://doi.org/10.1161/01.res.87.10.840
Schulz E, Gori T, Munzel T. Oxidative stress and endothelial dysfunctionin hypertension. Hypertension Research. 2011;34(6):665-673. https://doi.org/10.1038/hr.2011.39
Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Message 1: results of experimental studies. Advances in Gerontology. 2013;3:225-235.
Sokolova IB. Effect of peptide bioregulator of blood vessels on microcirculation in the cerebral cortex of old rats with arterial hypertension. Advances in Gerontology. 2017;30(4):534-537. (In Russ.).
Ryzhak AP, Kuznik BI, Rutkovskaya VN, et al. Antiatherosclerotic effect of a peptide geroprotector. Advances in Gerontology. 2012;25(1):139-142. (In Russ.).
Suchkov IA, Kalinin RE, Mzhavanadze ND, et al. Efficacy and safety of a drug based on regulatory polypeptides of vessels for treatment of intermittent claudication (results of a multicenter, double-blind, placebo-controlled randomized trial). Angiology and Vascular Surgery. 2023;29(1). (In Russ.).

Close metadata